

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: धारारुकेडु99@डुडुडु.डु

Date: 2nd July, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir / Madam,

Sub: Outcome of Board Meeting held today i.e. 2nd July, 2026

Ref: Security Id: DPL / Code: 543594

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held today i.e., 2nd July, 2026, at the Registered Office of the Company situated at A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad – 380 055 which commenced at 4:00 P.M. and concluded at 8:00 P.M. has inter-alia, considered and approved;

1. Audited Financial Results of the Company for the Quarter and Year ended on 31st March, 2026 along with Auditor's Report.
2. Statement of Deviations/ Variations for the proceeds of Preferential Issue – Convertible Warrants for the Year ended on 31st March, 2026 as per Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on your record and oblige us.

Thanking You

For, Dipna Pharmachem Limited


Keyur Dipakkumar Shah
Managing Director
DIN: 03167258



STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE MONTHS AND YEAR ENDED ON 31ST MARCH, 2026

(Amount Rs. in Lakhs)

Sr. No	Particulars	Quarter ended			Year ended		Previous Year ended
		March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025	March 31, 2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Income						
	Revenue from operations						
	a. Sale of Products and Services	202.49	5,351.72	1,591.68	12,908.33	12,491.71	12,491.71
	b. Other operating income	2.54	-	-	2.54	1.28	1.28
	Other Income						
	Total Income	205.03	5,351.72	1,591.68	12,910.87	12,492.99	12,492.99
2	Expenses						
	a. Purchase of stock-in-trade	1,354.20	3,944.66	973.77	12,237.20	10,378.03	10,378.03
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(1,542.76)	758.80	50.67	(1,489.05)	994.69	994.69
	c. Employee benefits expense	10.37	10.36	9.63	41.12	41.74	41.74
	d. Finance costs	23.14	23.38	60.18	146.32	231.99	231.99
	e. Depreciation and amortization expense	0.44	0.45	0.29	1.43	1.14	1.14
	f. Other expenses	336.98	470.52	428.72	1,614.90	702.18	702.18
	g. Power and Fuel	0.38	2.02	0.67	4.47	1.20	1.20
	Total Expenses	182.75	5,210.19	1,523.93	12,556.39	12,350.97	12,350.97
3	Profit before Exceptional items and tax (1-2)	22.28	141.53	67.75	354.48	142.02	142.02
4	Exceptional items	-	-	-	-	-	-
5	Profit before tax (3-4)	22.28	141.53	67.75	354.48	142.02	142.02
6	Tax expense						
	a. Current Tax	4.77	37.32	17.62	91.66	44.63	44.63
	b. Deferred Tax	(0.35)	-	-	(0.37)	(0.01)	(0.01)
	Total Tax Expense	4.42	37.32	17.62	91.29	44.62	44.62
7	Net profit/(Loss) for the period (5-6)	17.86	104.21	50.13	263.19	97.40	97.40
8	Other Comprehensive income						
	(Item that will not be reclassified to profit or loss (net of tax))	-	-	-	-	-	-
9	Total Comprehensive income (after taxes) (7+8)	17.86	104.21	50.13	263.19	97.40	97.40
10	Paid up equity share capital (Face value of Rs.10/- each)	2,628.92	2,628.92	2,404.53	2,628.92	2,404.53	2,404.53
11	Other equity (Reserves)	1,774.39	1,774.39	1,444.75	1,774.39	1,444.75	1,444.75
12	Earning per equity share						
	a. Basic	0.07	0.40	0.21	1.00	0.41	0.41
	b. Diluted	0.07	0.40	0.21	1.00	0.41	0.41

Notes:

- Number of Investors companies received, disposed of and lying unresolved as on 31.03.2026: Nil
- The above results have been reviewed by audit committee and approved by the Board of Directors at their meeting held on 2nd July, 2026
-
- The Company does not have any subsidiary company.
- The Company has, for the first time adopted IND AS during the period and accordingly the above Audited Financial Results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under.
- As the Company is having two segments during the year i.e. Steel & Chemicals segment, there are reportable segment in accordance with the requirement of IND AS-108 "Segment Reporting" specified under Section 133 of the Companies Act, 2013.

Place : Ahmedabad
Date : 02-07-2026



For, Dipna Pharmachem Ltd.
(Signature)
Keyur Shah
Managing Director
DIN:03167258



Dipna Pharmachem Limited		
CIN : L24100GJ2011PLC066400		
Add: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055		
Phone No :- 9898066121		
Email Id :- dharachem99@yahoo.in / info@dipnapharmachem.com		
Balance Sheet as at 31st March, 2026		
		(Amount Rs. in Lakhs)
Particulars	As at 31/03/2026	As at 31/03/2025
(1) ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	7.23	4.59
(b) Capital work-in-progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible assets	0.00	0.00
(f) Intangible assets under evelopment	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(b) Financial Assets	0.00	0.00
(i) Investments	0.00	0.00
(ii) Loans	5116.42	4070.13
(ii) Deferred Tax Asset (net)	0.66	0.29
(iv) Others	29.64	29.07
(c) Deferred tax assets (net)	0.00	0.00
(j) Other non-current assets	0.00	0.00
	5153.95	4104.07
Current assets		
(a) Inventories	4232.54	2743.49
(b) Financial Assets	0.00	0.00
(i) Investments	0.00	0.00
(ii) Trade receivables	4800.45	4733.06
(iii) Cash and cash equivalents	86.30	42.57
(iv) Bank balances other than (iii) above	32.90	39.31
(v) Loans and Advances	0.00	0.00
(vi) Current Tax Assets (Net)	0.00	0.00
(vii) Other current assets	6256.80	1575.53
	15408.99	9133.96
Total Assets	20562.94	13238.03
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	2628.92	2404.53
(b) Other Equity	1774.39	1444.75
(c) Share warrant money received	1827.01	0.00
	6230.32	3849.28
LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities	0.00	0.00
(i) Borrowings	1010.01	1101.51
(ii) Trade payables	0.00	0.00
(iii) Other financial liabilities (other than those specified in item (b), to be specified)		0.00
(b) Provisions	0.00	0.00
(c) Deferred tax liabilities (Net)		0.00
(c) Other non-current liabilities	0.00	0.00
(d) Deferred Tax Liability (net)	0.00	0.00
	1010.01	1101.51
Current liabilities		
Financial Liabilities		
(i) Borrowings	311.09	620.90
(ii) Trade payables	0.00	0.00
(iii) Other financial liabilities (other than those specified in item (c))	0.00	0.00
(b) Other current liabilities		
a. total outstanding dues of micro enterprises and small enterprises; and	9210.18	4085.51
b. total outstanding dues of creditors other than micro enterprises and small enterprises	1824.08	3049.46
Provisions		0.00
(c) Current Tax Liabilities (Net)	117.78	54.19
(d) Other Current Liabilities	1859.48	477.20
Total Current Liability	13322.60	8287.24
Total Equity and Liabilities	20562.94	13238.03

For and on behalf of the Board of Directors of
Dipna Pharmachem Ltd.



Keyur Shah
Keyur Shah
Managing Director
DIN:03167258

Place: Ahmedabad
Date: 02/07/2026

Dipna Pharmachem Limited		
CIN : L24100GJ2011PLC066400		
Add: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055		
Phone No :- 9898066121		
Email Id :- dharachem99@yahoo.in / info@dipnapharmachem.com		
Cashflow Statement for the period ended on 31st March, 2026		
(Amounts in Lacs)		
Particulars	2025-26	2024-25
Cash flow from operating activities:		
Profit before tax from continuing operations	354.48	142.02
Adjustment to reconcile profit before tax to net cash flows		
Bad Debt	0.00	0.00
Depreciation	1.43	1.14
Loss on sale of Property, Plant and Equipment	0.00	0.00
Finance Cost	146.32	201.57
Operating profit before working capital changes	502.23	344.73
Movements in working capital :		
Increase/(decrease) in current liabilities & provisions		
Decrease/(increase) in inventories	(1,489.05)	994.69
Decrease/(increase) in Trade Payables	3,899.30	118.95
Decrease/(increase) in Debtors	(67.39)	(1,533.90)
Decrease/(increase) in other current assets	(5,721.72)	(752.54)
Increase /(Decrease) in Other Current Liabilities	1,072.47	19.89
Increase /(Decrease) in Short Term Provisions	63.59	(66.65)
Cash Generated from/(used in) operations	(1,740.57)	(874.83)
Direct Taxes paid (net of refunds)	91.66	44.63
Net cash flow from /(used in) operating activities (A)	(1,832.23)	(919.46)
Cash flow from investing activities		
Purchase of fixed assets	(4.07)	(2.01)
Sales of fixed assets	-	-
Investment	-	-
Net cash flow from/(used in) investing activities (B)	(4.07)	(2.01)
Cash flow from financing activities		
Proceed from issue of Equity shares	224.39	
Proceed from Issue of share warrants	1,827.01	
Proceed from Share Premium	66.45	-
Increase / (Decrease) in Secured Borrowings	(91.50)	(222.22)
Increase / (Decrease) in Unsecured Borrowings		-
Interest Paid	(146.32)	(201.57)
Net cash flow from/(used in) financing activities (C)	1,880.03	(423.79)
Net increase/decrease in cash & cash equivalents (A+B+C)	43.73	(1,345.26)
Cash & cash equivalents at the beginning of the year	42.57	1,387.83
Cash & cash equivalents at the end of the year	86.30	42.57
For and on behalf of the Board of Directors of Dipna Pharmachem Ltd.		
Place: Ahmedabad		
Date- 02/07/2026	 Keyur Shah Managing Director DIN:03167258	

DIPNA PHARMACHEM LIMITED							
CIN : L24100GJ2011PLC066400							
Add: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055							
Phone No :- 9898066121							
Email Id :- dharachem99@yahoo.in / info@dipnapharmachem.com							
SEGMENT WISE STANDALONE REVENUE, RESULTS, ASSETS AND LIABILITIES							
(Amount Rs. in Lakhs)							
Sr. No	Particulars	Quarter ended			Year ended		Previous Year ended
		March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025	March 31, 2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Income						
	Segment Revenue from operations						
	a. Sale of Products and Services						
	Chemicals Segment	202.49	2,625.04	10.93	5,819.19	10,910.96	10,910.96
	Steel Segment	-	2,726.68	1,580.75	7,089.14	1,580.75	1,580.75
	Total Segment Revenue	202.49	5,351.72	1,591.68	12,908.33	12,491.71	12,491.71
2	Segment Results						
	a. Chemicals Segment	(61.08)	(182.43)	50.03	(512.35)	124.30	124.30
	b. Steel Segment	83.36	323.96	17.72	866.83	17.72	17.72
	Total Segment Result	22.28	141.53	67.75	354.48	142.02	142.02
3	Segment Assets						
	a. Chemicals Segment	4,081.36	4,569.87	4,546.62	4,081.36	4,546.62	4,546.62
	b. Steel Segment	719.09	-	186.44	719.09	186.44	186.44
	Total Segment Assets	4,800.45	4,569.87	4,733.06	4,800.45	4,733.06	4,733.06
4	Segment Liabilities						
	a. Chemicals Segment	8,935.98	7,647.44	6,958.33	8,935.98	6,958.33	6,958.33
	b. Steel Segment	2,098.28	-	176.64	2,098.28	176.64	176.64
	Total Segment Liabilities	11,034.26	7,647.44	7,134.97	11,034.26	7,134.97	7,134.97

Place : Ahmedabad
Date : 02-07-2026



For, Dipna Pharmachem Ltd.

Keyur Shah

Keyur Shah
Managing Director
DIN:03167258



Independent Auditor's Report on Audited Standalone Half Yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

INDEPENDENT AUDITOR'S REPORT

**TO THE BOARD OF DIRECTORS OF
DIPNA PHARMACHEM LIMITED**

Report on the audit of the Standalone Financial Results

Opinion


We have audited the accompanying standalone quarterly financial results of Dipna Pharmachem Limited ("the Company") for the quarter ended on 31st March, 2026 and the year to date results for the period from 1st April, 2025 to 31st March, 2026 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended on 31st March, 2026 as well as the year to date results for the period from 1st April, 2025 to 31st March, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





Emphasis of Matter Paragraph

Our opinion is not modified in respect of this matter.

Management's Responsibilities for the Standalone Financial Results

These standalone quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:





DEVADIYA & ASSOCIATES

CHARTERED ACCOUNTANTS

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all Relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For, Devadiya & Associates
Chartered Accountants
FRN: 123045W

CA Sanjay Devadiya
Partner
Membership No. 112495
UDIN: 26112495PODYPB8261
Date: 2ND July, 2026
Place: Ahmedabad



DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad - 380 055

E-mail: dharachem99@yahoo.in

Date: 2nd July, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai - 400 001.

Dear Sir / Madam,

**Sub: Declaration in respect of Unmodified Opinion on Audited Financial Result for the
Half year and Financial Year ended on 31st March, 2026**

Ref: Security Id: DPL / Code: 543594

We hereby declared that the Statutory Auditor of the Company, M/s. Devadiya & Associates, Chartered Accountants, has issued Audit Report with Unmodified Opinion on Audited Financial Result for the Half Year and Financial Year ended as on 31st March, 2026.

The declaration is given in compliance to second proviso of Reg. 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment), Regulations 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001, dated 25th May, 2016.

Kindly take the same on your record and oblige us.

Thanking You.

For, Dipna Pharmachem Limited


Keyur Dipakkumar Shah
Managing Director
DIN: 03167258



DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: धारारुकेडु99@yahoo.in

Statement of Deviation or Variation in Utilization of Funds Raised through Preferential Issue

Name of listed entity	Dipna Pharmachem Limited
Mode of Fund Raising	Preferential Issue – Convertible Warrants
Date of Raising Funds	24 th February, 2025
Amount Raised	Allotment of 22,44,000 Equity shares pursuant to conversion of convertible warrants against the receipt of Rs. 2,19,63,150.00/- in the Board Meeting held on 29 th November, 2025, which together represent 75.00% of the total consideration for the issue.
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the Unit holders	Not Applicable
If Yes, Date of Unit holders Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

Set forth below are objects for which funds have been raised and where there has been a deviation, in the following table:

Object for utilization of Issue Proceeds	Modified Object, if any	Original Allocation (Amount in Lakh)	Modified Allocation if any	Funds Utilised (Amount in Lakh)*	Amount of Deviation/ Variation for Quarter according to applicable object	Remarks if any
To Meet Working Capital Requirements	N.A.	Rs. 7497.71/-	Rs. 5679.93/-	Rs. 1584.71/-	-	N.A.
General Corporate Purpose	N.A.	Rs. 2499.24/-	Rs. 1893.31/-	Rs. 528.24/-	-	N.A.

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: [dharachem99@yahoo.in](mailto:धारारुकेडु99@डुहूडु.डु)

**The Company received 25.00% of the total consideration for 5,80,32,500 convertible warrants at a price of Rs. 13.05/- per warrant, aggregating to Rs. 18,93,31,031/-, in the Board Meetings held on 9th September 2025 and 12th September 2025.*

**The Company received 75.00% of the total consideration for 22,44,000 equity shares, allotted pursuant to the conversion of warrants at a price of Rs. 13.05/- per share, aggregating to Rs. 2,19,63,150/-, in the Board Meeting held on 29th November 2025.*

We further certify that there are **no deviation(s) or variation(s)** in respect of the utilization of the funds of Preferential issue of Convertible Warrants ("Warrants") of the Company during the **Half and year ended on 31st March, 2026.**

Deviation or variation could mean:

- A. Deviation in the objects or purposes for which the funds have been raised or
- B. Deviation in the amount of funds actually utilized as against what was originally disclosed or
- C. Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

For, Dipna Pharmachem Limited



Keyur Dipakkumar Shah
Managing Director
DIN: 03167258

